Helicos' Cash Decreases to $200K; CEO Goes Part-Time | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Helicos BioSciences said in a filing with the US Securities and Exchange Commission Friday that it has approximately $200,000 in cash and cash equivalents remaining and will require "significant additional capital" to continue operations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.